Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy

Pek Keng Koh*, Corinne Faivre-Finn, Fiona H. Blackhall, Dirk De Ruysscher

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

67 Citations (Web of Science)


In recent years there has been undoubted progress in the evaluation and development of targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the discovery of molecular subtypes harbouring a critical oncogenic driver mutation, specifically sensitizing mutations in the epidermal growth factor receptor (EGFR) gene and the EML4-ALK gene translocation. Radiotherapy is a cornerstone of therapy for the curative intent treatment of early stage, localized disease; and for the palliation of symptoms in advanced, metastatic disease. In this molecular targeted era there is limited understanding of how best to combine targeted agents with radiotherapy and in general clinical studies with radiotherapy have lagged behind studies of targeted agents with chemotherapy. Here we summarise the progress made to date and highlight future directions.
Original languageEnglish
Pages (from-to)626-640
JournalCancer Treatment Reviews
Issue number6
Publication statusPublished - Oct 2012


  • Non-small cell lung cancer
  • Targeted agents
  • Chemoradiotherapy
  • EGFR inhibitors
  • Antiangiogenic agents
  • Phase I trials
  • Preclinical models
  • Radiotherapy
  • Combined modality treatment

Cite this